| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
NRX Pharmaceuticals (NASDAQ:NRXP) is gearing up to announce its quarterly earnings on Thursday, 2025-08-14. Here's a quick overview of what investors should know before the release.
Analysts are estimating that NRX Pharmaceuticals will report an earnings per share (EPS) of $-0.23.
Anticipation surrounds NRX Pharmaceuticals's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
In the previous earnings release, the company missed EPS by $0.09, leading to a 2.08% increase in the share price the following trading session.
Here's a look at NRX Pharmaceuticals's past performance and the resulting price change:
| Quarter | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| EPS Estimate | -0.25 | -0.69 | -0.58 | |
| EPS Actual | -0.34 | -0.77 | -0.15 | -0.75 |
| Price Change % | 2.0% | 7.000000000000001% | 3.0% | -6.0% |
Shares of NRX Pharmaceuticals were trading at $2.39 as of August 12. Over the last 52-week period, shares are up 42.53%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release.
To track all earnings releases for NRX Pharmaceuticals visit their earnings calendar on our site.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: NRXP
